Efficacy and Safety of Cadonilimab, An Anti-PD-1/CTLA4 Bi-specific Antibody, in Previously Treated Recurrent or Metastatic (R/M) Cervical Cancer: A Multicenter, Open-label, Single-arm, Phase II Trial (89). Here, CTLA4 is linked to cervical cancer.